Bioactive Compound Library 
It contains more than 19730 small molecule compounds, with known biological activities causing biological reaction in cells, tissue even whole body, including Clinical compound library (L3400), Preclinical compound library (L3410), and Approved drug library (L1000). All compounds have clear targets and detailed information description, which is the key point to drug research and development like drug repurposing, small molecule inducing stem cell differentiation, and target identification in mechanism interrogation.
Many scientists have identified small molecules that can regulate cell fate and function, and stem cell differentiation by screening annotated bioactive compound library with confirmed activity and known targets. Recent advances in iPSC technology have made reprogramming of somatic cells towards pluripotency possible and simpler. Using both phenotypic screening and hypothesis-driven approaches, a growing number of compounds have been identified that can functionally replace reprogramming transcription factors, enhance efficiency of iPSC generation and accelerate the reprogramming process by single use or a combination of several molecules with success in cardiomyocyte differentiation and proliferation, neural progenitor cells, etc.
- All products & services are for research use only. Not for human or veterinary or therapeutic use.
- Pack Size
- 1 mg
- 10 μL x 10 mM (in DMSO)
- 30 μL x 10 mM (in DMSO)
- 50 μL x 10 mM (in DMSO)
- 100 μL x 10 mM (in DMSO)
Technical Information
Library Compound Information
Excel 
SDF - Packaging And Storage:
- Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
- Shipped with blue ice
- This compound library is provided at a concentration of 10 mM in DMSO. A small number of compounds may be provided in different solvents or concentrations due to solubility or stability requirements. Please refer to the specific product information for details.
- Product Description:
- A collection of 19730 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;
- All compounds have clear targets;
- An effective tool for discovering new with old drugs, cell induction, and new drug target screening;
- Covers various disease research areas, such as Cancer, Metabolism, Immunology and Cardiovascular system, etc.
- Detailed compound information with structure, target, activity, IC50 value, and brief introduction;
- Structurally diverse, medicinally active, and cell permeable;
- NMR and HPLC validated to ensure high purity and quality;
- Advantages Introduction:
High-Standard Entry Criteria
TargetMol's Bioactive Compounds Library is established upon rigorous entry standards to ensure that every compound included is structurally well-defined and of exceptional purity, verified through multiple analytical techniques such as NMR, HPLC, and LC-MS. Our multi-layered screening mechanism effectively eliminates compounds with ambiguous structures, such as mixtures and polymers. Moreover, we specifically exclude substances like sunscreens, contrast agents, dyes, fragrances, plastic additives, and intermediates—compounds typically lacking biological activity due to their specificity and stability, which generally prevent interactions with biological systems. This meticulous curation reduces time and resource waste caused by ineffective screenings.
Significant Structural Diversity
TargetMol’s Bioactive Compounds Library features extensive scaffold diversity and structural complexity, offering a substantial advantage in drug discovery. Based on the Bemis-Murcko scaffold classification, our library is categorized into 10,102 unique classes, each representing a distinct molecular scaffold, thereby extensively covering a broad chemical space. The compounds range from simple to highly complex structures, providing a diverse foundation for identifying lead compounds with strong affinity and specificity toward target proteins. This structural richness significantly advances pharmaceutical innovation. Whether targeting traditional drug targets or emerging, more challenging ones, our Bioactive Compounds Library offers a wealth of candidate molecules to accelerate the drug development process.
Library Diversity AnalysisSuperior Drug-Like Properties
67% of the compounds in TargetMol's Bioactive Compounds Library comply with Lipinski’s "Rule of Five" (Ro5), indicating excellent bioavailability and permeability.
Multidimensional Pharmacokinetic Analysis
A multidimensional evaluation is conducted on TargetMol’s Bioactive Compounds Library, which systematically analyzes three key pharmacological parameters: blood-brain barrier permeability, cardiotoxicity (HERG K+ channel inhibition), and oral absorption performance.
14% of the compounds can cross the blood-brain barrier, while 86% cannot.
49% of the compounds exhibit cardiotoxicity, while 51% do not.
54% of the compounds are highly orally absorbable.Diverse Compound Collection
TargetMol's Bioactive Compound Library covers a wide variety of compounds with diverse biological activities. This includes marketed drugs, drug candidates in clinical trials, and compounds with reported biological activities in the literature. The library encompasses not only mainstream signaling pathways and targets but also numerous emerging therapeutic targets. It spans various therapeutic areas, including cancer, cardiovascular diseases, and neurological disorders.
Regular Updates to Compound Libraries
We ensure our compound libraries remain at the forefront of scientific research by regularly updating our database with compounds mentioned in cutting-edge literature and newly custom-synthesized compounds.
Flexible Packaging Options
We offer a variety of standard packaging sizes (e.g., 30 μL, 50 μL, 100 μL, 250 μL, 1 mg), and we can customize packaging solutions to meet specific needs.
Customized Services
To support specific needs, we offer tailored screening services, including the design and synthesis of customized compound libraries and the execution of personalized screening projects. Our highly flexible service model is designed to efficiently meet unique needs of scientists and accelerate breakthrough discoveries.
